Reading your LH result across the cycle and between the sexes

What luteinizing hormone (LH) actually is

LH is a signaling protein made by the pituitary gland. It travels through the bloodstream to the gonads, where it triggers ovulation and progesterone production in women and stimulates Leydig cells in the testes to synthesize testosterone in men. LH is released in pulses driven by GnRH from the hypothalamus, making it a direct readout of the brain's reproductive signaling at any given moment.

The brain-to-gonad signal that LH actually carries

The hypothalamus releases GnRH in rhythmic bursts, prompting the pituitary to release matching LH pulses. Those pulses keep ovaries and testes responsive without desensitizing their receptors. In the female cycle, rising estradiol before ovulation flips the pituitary from negative to positive feedback, producing the LH surge that ovulation kits detect. Ovulation follows, the follicle luteinizes, and progesterone rises. In the luteal phase, higher progesterone and moderate estradiol suppress LH again. In men, LH pulses throughout the day, driving testosterone synthesis, which then feeds back to stabilize LH output.

Sleep, energy balance, and illness can dampen those pulses — people who are underfueled or under chronic stress often show blunted LH. With aging, women transition through perimenopause to menopause, where LH rises as ovarian reserve falls. In men, LH may also rise as the testes become less responsive, resulting in higher LH for the same or lower testosterone. LH does not measure ovarian reserve directly; it reflects the brain's current signaling intensity, not the number of remaining follicles.

Several factors can distort a single LH reading. High biotin intake can interfere with immunoassay platforms, producing falsely elevated or suppressed results. hCG, produced by the placenta and structurally similar to LH, can cross-react with some assays, misleading results during early pregnancy, postpartum, or perimenopause. Because LH is pulsatile, a single blood draw captures only a snapshot; the value can shift meaningfully within hours depending on where in a pulse cycle the sample was taken.

Reading your LH number by cycle phase and sex

Lab reference ranges describe what is common in a tested population, not what is ideal for any individual. They vary by lab, assay, and life stage, so the numbers below are representative guides rather than universal cutoffs. In women, a meaningful LH result requires knowing cycle day; in men, it requires pairing with testosterone. Representative ranges: early follicular phase 2–15 IU/L, luteal phase 1–7 IU/L, mid-cycle surge 25–40+ IU/L, and men 1.7–8.6 IU/L. The concept of "optimal" is more nuanced than population-derived normals suggest — for women trying to conceive, an LH surge aligned with other ovulation signs is a positive signal; for men, LH appropriate for the testosterone level indicates the brain and testes are communicating well.

Normal LH

An LH result within the phase-appropriate reference range, drawn at the right time in the cycle or as a morning sample in men, generally reflects intact hypothalamic-pituitary-gonadal communication. In women, this means a modest follicular-phase value, a clear mid-cycle surge, and a lower luteal-phase reading. In men, a value in the 1.7–8.6 IU/L range alongside a normal testosterone suggests the axis is functioning as expected. Because LH is pulsatile, a single normal result is reassuring but not definitive; trends across visits carry more weight than any one draw.

High LH

In women, high LH around mid-cycle is expected — it is the ovulatory surge. Persistently high LH outside the surge can occur with low ovarian reserve or menopause, where the brain increases signaling intensity because the ovaries are less responsive. Some women with polycystic ovary syndrome have a relatively elevated LH compared to FSH, reflecting altered feedback and ovarian signaling, though this ratio is neither necessary nor sufficient for diagnosis.

In men, high LH paired with low testosterone suggests the testes are not responding adequately, a pattern seen with primary testicular failure from aging, prior chemotherapy, genetic conditions, or injury. High LH with normal or high testosterone can appear if the assay is affected by interfering antibodies or if there is intermittent Leydig cell dysfunction. Estrogen blockers and androgen deprivation therapies raise LH by design. Thyroid and prolactin disorders can shift the whole axis, and high biotin intake can produce falsely elevated readings on some platforms. Timing, repeat testing, and partner hormones are essential before drawing conclusions.

Low LH

A low LH in women can reflect a normal early follicular or luteal phase. Outside those windows, persistently low LH can signal hypothalamic or pituitary suppression from energy restriction, high training load, psychological stress, or elevated prolactin. Many athletes with functional hypothalamic amenorrhea show blunted LH pulses alongside low estradiol and absent ovulation.

In men, low LH with low testosterone points to a central issue in the hypothalamus or pituitary. Causes include sleep debt, obesity, opioids, glucocorticoids, and some psychiatric medications. Elevated prolactin is a well-established suppressor. Acute illness can also blunt LH temporarily while the body prioritizes recovery. Pregnancy is its own category: hCG takes over luteal support and can cross-react with LH assays, and urine ovulation kits can give misleading readings during postpartum or perimenopause. If results do not fit the clinical picture, assay type, supplement use, and sample timing are all worth reviewing.

Why LH pulses shift from draw to draw

LH is pulsatile by design, so draw timing alone introduces variability. Beyond that, several physiological and pharmacological factors shift the underlying pulse pattern.

Energy availability is a primary driver. Energy restriction suppresses GnRH pulse frequency, which reduces LH output. This is seen in athletes with high training loads and insufficient caloric intake, and in anyone in a prolonged energy deficit. Iron deficiency, common in menstruating athletes, adds metabolic stress that can indirectly dampen the axis.

Sleep and cortisol interact directly with the hypothalamus. LH pulses are partly nocturnal; poor sleep raises stress signals that inhibit GnRH, compressing the pulse pattern. Shift work, irregular sleep schedules, and chronic psychological stress travel the same pathway, nudging the brain toward conservation rather than reproductive signaling.

Medications are a significant source of LH suppression. Combined hormonal contraception suppresses LH and prevents ovulation by design. In men, exogenous androgens and anabolic steroids suppress LH, often profoundly. Opioids, glucocorticoids, and some psychiatric medications can also dampen the axis. Elevated prolactin — from a pituitary adenoma or dopamine-blocking medications — suppresses GnRH upstream, lowering LH even when the gonads are fully responsive.

Assay interference is a practical confounder. High biotin intake can distort immunoassay-based LH results. Reviewing supplements with a clinician before testing reduces this source of noise. Life stage also shifts the baseline: puberty brings LH online, pregnancy replaces LH signaling with hCG, perimenopause raises LH as ovarian responsiveness falls, and aging in men may produce rising LH for the same testosterone output.

The hormones that read LH in context

• Follicle-stimulating hormone (FSH) — FSH and LH together map the pituitary-gonadal axis; high LH combined with high FSH and low estradiol or testosterone separates primary gonadal failure from central suppression.
• Estradiol — estradiol's feedback on LH determines whether a high LH reflects the ovulatory surge or a loss of ovarian response; a critical pairing in women.
• Total testosterone — in men, LH with testosterone distinguishes primary testicular failure (high LH, low testosterone) from central hypogonadism (low LH, low testosterone).
• Prolactin — elevated prolactin suppresses GnRH, producing low LH even when the gonads are responsive; rules out a correctable upstream cause.
• AMH (anti-Müllerian hormone) — AMH reflects ovarian reserve independent of cycle timing; pairing with LH and FSH reveals whether the brain is signaling harder because the ovarian reserve is diminishing.

When to recheck LH after a change

LH responds to changes in the hypothalamic-pituitary-gonadal axis within weeks, but a single retest draw can still be misleading given the hormone's pulsatile nature. When titrating therapy with a GnRH agonist, enclomiphene, or hCG, a response window of roughly 4–8 weeks is typical; hypothalamic recovery after a period of suppression follows a similar timeline. Retesting at 2–3 months is a reasonable interval when actively adjusting treatment.

Outside of active therapy, LH is best rechecked every 6–12 months as part of a hormonal baseline, or sooner if symptoms change. Timing the draw matters as much as the interval: in women, a cycle day 2–5 early-follicular draw provides the most reproducible baseline; in men, a morning draw reduces diurnal noise. Using the same laboratory and the same draw-day protocol across visits improves comparability. Because a single LH value carries inherent snapshot noise, trending the mean across multiple visits is more informative than reacting to any one result.

When an LH result warrants a clinician conversation

Testing gives you timing and trends. For women, tracking LH across a cycle or using urine LH kits can pinpoint the fertile window and confirm the surge, especially when paired with temperature or progesterone. For men, pairing LH with a morning testosterone clarifies whether low energy or libido stems from the testes or from the signals above them. Anchoring results to cycle day, training load, sleep patterns, and life stage turns scattered data points into an interpretable pattern.

A clinician conversation is warranted when LH is persistently elevated outside the expected mid-cycle window in women, when LH is low alongside absent periods or low testosterone, when LH and testosterone are discordant in a way that suggests primary or central dysfunction, or when results shift unexpectedly between draws without a clear lifestyle explanation. These patterns can reflect conditions — from functional hypothalamic amenorrhea to primary gonadal failure to a prolactin-secreting adenoma — that benefit from further evaluation and, where appropriate, treatment.

Viewing LH alongside FSH, estradiol or testosterone, prolactin, and metabolic markers moves the picture from a single number to a full-scene view of reproductive and hormonal health. Superpower is built around that approach — connecting comprehensive biomarker data with clinician interpretation so results reflect your pattern, not just a population average. Learn more about the thinking behind it at our manifesto.